The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, the gravity of unmet need, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Biosimilars in Pharmaceuticals: Coagulation factor-based compositions.
According to GlobalData’s Technology Foresights, which uses over 756,000 patents to analyse innovation intensity for the pharmaceutical industry, there are 110 innovation areas that will shape the future of the industry.
Coagulation factor-based compositions is a key innovation area in biosimilars
Coagulation factors also called clotting factors are blood proteins that help form blood clots on injuries to prevent bleeding. Coagulation factor concentrates are drugs used to manage bleeding in blood clotting disorders such as Haemophilia or Von Willebrand Disease. They can control, prevent, and decrease the frequency of bleeding episodes and prevent bleeding during surgery, by the activation of the prothrombin complex which induces clotting of blood. A biosimilar is a biological product that shares many characteristics with a reference biologic and doesn’t exhibit any clinically significant variations in terms of safety, purity, or potency.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 50+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of coagulation factor-based compositions.
Key players in coagulation factor-based compositions – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to coagulation factor-based compositions
| Company | Total patents (2010 - 2021) | Premium intelligence on the world's largest companies |
| Novo Nordisk Foundation | 346 | Unlock company profile |
| Sanofi | 325 | Unlock company profile |
| Takeda Pharmaceutical | 198 | Unlock company profile |
| Bayer | 189 | Unlock company profile |
| Moderna | 178 | Unlock company profile |
| Biogen | 176 | Unlock company profile |
| LFB | 122 | Unlock company profile |
| Children's Hospital of Philadelphia | 115 | Unlock company profile |
| Catalyst Biosciences | 95 | Unlock company profile |
| Amunix Operating | 95 | Unlock company profile |
| Baxter International | 93 | Unlock company profile |
| CSL | 92 | Unlock company profile |
| Sangamo Therapeutics | 75 | Unlock company profile |
| Teva Pharmaceutical Industries | 45 | Unlock company profile |
| GLAdiator Biosciences | 44 | Unlock company profile |
| Coagulant Therapeutics | 39 | Unlock company profile |
| DRK-Blutspendedienst Baden-Wurttemberg-Hessen | 34 | Unlock company profile |
| Johnson & Johnson | 32 | Unlock company profile |
| Pfizer | 31 | Unlock company profile |
| OPKO Health | 25 | Unlock company profile |
| F. Hoffmann-La Roche | 25 | Unlock company profile |
| PDS Biotechnology | 23 | Unlock company profile |
| Nektar Therapeutics | 21 | Unlock company profile |
| Alkermes | 19 | Unlock company profile |
| Emergent BioSolutions | 18 | Unlock company profile |
| Octapharma | 17 | Unlock company profile |
| Life Sciences Research Partners VZW | 16 | Unlock company profile |
| Regeneron Pharmaceuticals | 14 | Unlock company profile |
| Intellia Therapeutics | 14 | Unlock company profile |
| Medexus Pharmaceuticals | 14 | Unlock company profile |
| Cell Machines | 13 | Unlock company profile |
| Hanmi Science | 13 | Unlock company profile |
| CNJ Holdings | 13 | Unlock company profile |
| BioMarin Pharmaceutical | 12 | Unlock company profile |
| Alveron Pharma | 12 | Unlock company profile |
| Xenetic Biosciences | 12 | Unlock company profile |
| Glycotope | 12 | Unlock company profile |
| Alnylam Pharmaceuticals | 12 | Unlock company profile |
| Maxygen | 12 | Unlock company profile |
| ToolGen | 11 | Unlock company profile |
| DRK-Blutspendedienst Ost gemeinnutzige | 11 | Unlock company profile |
| SK Chemicals | 11 | Unlock company profile |
| Swedish Orphan Biovitrum | 11 | Unlock company profile |
| Beehive Capital LLP | 10 | Unlock company profile |
| Children's Healthcare of Atlanta | 9 | Unlock company profile |
| Poseida Therapeutics | 9 | Unlock company profile |
| Eio Biomedical | 8 | Unlock company profile |
| CRISPR Therapeutics | 7 | Unlock company profile |
| Meiji Holdings | 7 | Unlock company profile |
| Octapharma Biopharmaceuticals | 7 | Unlock company profile |
Source: GlobalData Patent Analytics
Novo Nordisk is a leading global healthcare company focused on discovering, developing, and manufacturing innovative biological medicines. It focuses on advancing drugs for the treatment of diabetes and other serious chronic conditions, including haemophilia, human growth hormone (HGH) disorders, and obesity. The company has made long-term investments in novel treatments and technologies, including curative stem cell-based therapies, to continually advance the development of novel therapies. Novo Nordisk is dedicated to improving access to quality care for people with haemophilia and rare bleeding disorders in developing and emerging countries. Novo Nordisk has an agreement to license 2seventy bio’s proprietary mRNA-based megaTAL™ technology for the development of a new treatment approach for haemophilia.
In terms of application diversity, Alveron Pharma is the top company followed by Cell Machines Inc. and Swedish Orphan Biovitrum AB. By means of geographic reach, PDS Biotechnology Corp holds the top position. Teva Pharmaceutical Industries Ltd and Intellia Therapeutics Inc are in the second and third positions, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox